Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Ameet Mallik is Chief Executive Officer at Adc Therapeutics. OQRO lists 4 transactions filed with the SEC under this name, the latest on Jul 2, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
4
Companies involved
1
Adc TherapeuticsADCT
4 disclosures · Dec 2025 – Jul 2026
Jun 30, 2026675Kdisclosed Jul 2
DetailsOfficial recordFeb 13, 2026900Kdisclosed Feb 18
DetailsOfficial recordFeb 13, 2026103Kdisclosed Feb 18
DetailsOfficial recordDec 6, 2025233Kdisclosed Dec 9
DetailsOfficial recordAmeet Mallik has no open-market purchase on record since 2024. Sales in 1 of the 3 years since 2024.
Ameet Mallik reported 0 open-market purchases and 1 sale since 2024; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $133K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Ameet Mallik reported holding 2,121,769 shares of Adc Therapeutics (ADCT), worth about $2.72M at the last close of $1 (Nov 20, 2026).
Adc Therapeutics's proxy statement reports total compensation of $2.45M for its chief executive for fiscal year 2025, after $1.84M for 2024. Ameet Mallik files with the SEC as Chief Executive Officer of Adc Therapeutics. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Apr 20, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Adc Therapeutics ADCT | 2,121,769 | 2.12M direct | $1 | $2.72M | Jun 30, 2026 |
Is this Ameet Mallik’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Jun 30, 2026, Ameet Mallik reported holding 2,121,769 shares of Adc Therapeutics (ADCT). At the last close of $1 on Nov 20, 2026, that is about $2.72M. This is the stake disclosed in filings, not a net worth.
No public filing gives Ameet Mallik's net worth. What SEC Form 4 shows is the stock stake: 2,121,769 shares of Adc Therapeutics (ADCT), about $2.72M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Adc Therapeutics's proxy statement reports total compensation of $2.45M for its chief executive for fiscal year 2025, after $1.84M for 2024. Ameet Mallik files with the SEC as Chief Executive Officer of Adc Therapeutics. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Ameet Mallik has no open-market purchase on record since 2024. Sales in 1 of the 3 years since 2024.
In SEC filings since 2024: no open-market purchase is on record; the latest open-market sale is from 2024.
Adc Therapeutics (ADCT), from 2024 to 2024: 0 purchases and 1 sale.
Ameet Mallik reported 0 open-market purchases and 1 sale here, 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.